CTIM-12. RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (rGBM)

BACKGROUND: Trials with anti-PD1 in rGBM have shown limited efficacy. VEGF is highly upregulated proangiogenic growth factor in GBM contributing to tumor-associated immunosuppression. Preclinical data suggests a potential dose effect of anti-VEGF therapy on immunomodulation. Hence, a combination of...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Ahluwalia, Manmeet, Peereboom, David, Rauf, Yasmeen, Lathia, Justin, Alban, Tyler, Schilero, Cathy, Ciolfi, Marci, LaForest-Roys, Corey, Nayak, Lakshmi, Lee, Eudocia, Wen, Patrick, Reardon, David
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2020
Konular:
Clinical Trials: Immunologic
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650408/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.146
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller